World's longest surviving liver‐pancreas recipient

Albert M. Harary, Kareem Abu‐Elmagd, Ngoc Thai, Ron Shapiro, Satoru Todo, John J. Fung, Thomas E. Starzl – 28 June 2007 – In July 1988, the liver and pancreas of a cadaveric donor were transplanted separately into a man with type 1 diabetes with end‐stage chronic hepatitis B virus. Two features of the operation may help explain the patient's current status as the longest‐lived liver‐pancreas recipient. One was enteric drainage of pancreatic exocrine secretions. The other was delivery of the pancreas venous effluent to the host portal system and then directly to the hepatic allograft.

Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: Outcome of hepatorenal transplantation

Adam G. Testro, Stephen O. Brennan, Richard A.L. Macdonell, Philip N. Hawkins, Peter W. Angus – 28 June 2007 – Liver transplantation (LT) has been reported in only 1 patient with hereditary variant apolipoprotein AI (apoAI) amyloidosis and was associated with a 50% decrease in production of variant apoAI. The potential for this to benefit clinical manifestations of apoAI amyloidosis such as peripheral neuropathy has not been determined.

Recurrent hepatocellular carcinoma is a problem we need to tackle

James D. Perkins – 28 June 2007 – Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria. We previously reported that Licartin ([131I]mAb HAb18G/CD147) was safe and effective in treating HCC patients, and its antigen, HAb18G/CD147, was closely related to HCC invasion and metastasis. Here, we reported a randomized controlled trial to assess the post‐OLT antirecurrence efficacy of Licartin in advanced HCC patients.

Subscribe to